C-H9L9Lionheart Health, Inc.
bioelectrics, biologics, regenerative medtech
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-H9L9
C-H9L9C-H9L9bioelectrics, biologics, regenerative medtech
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Howard J Leonhardt of Leonhardt Ventures is an entrepreneur, inventor, and candidate for governor of California in 2014. He owns over 20 patents and has created more than 20 companies including the California Stock Xchange, a vineyard, and an award winning restaurant in Florida. Tech Cocktail caught up with Leonhardt to learn more about the California Stock Xchange, his running for governor, and advice he offers to entrepreneurs. This interview was part of Tech Cocktail Sessions in San Francisco hosted at pariSoma. Read the full post at: http://tech.co Watch more entrepreneurial interviews at: http://tech.co/category/tech-cocktail-tv/interviews
Instagram Instagram Log In Sign Up Close Never miss a post from devindthorpe Sign up for Instagram to stay in the loop. Sign up Log in devindthorpe • Follow More options devindthorpe Edited • 319w Check out my latest video with Howard Leonhardt, founder of Leonhardt Ventures. We discuss innovative ideas, including organ regeneration. Link in bio!⠀ #utpol #utah #boldsolutions #plugintodevin Load more comments No comments yet. Start the conversation. Like 13 Comment Share Save April 20, 2020 Log in to like or comment. More posts from devindthorpe Clip See more posts Meta About Blog Jobs Help API
2024 Year End Update Leonhardt Ventures Portfolio - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Episode 138: Howard Leonhardt – The Future of Longevity & Wellness is Here! - Leonhardt Ventures Home About About us 2021 Top Achievements Leonhardt Ventures Portfolio Clinical Trials Listing Founder Bio Development Pipeline Investigator Initiated Study Request Procedure for Both Pre-Clinical and Clinical Studies Regenerative Medtech Media Company Logos LV Team Board of Directors Accelerator Core Team Portfolio Startups Boards Scientific Advisory Board Our Startups News Investors Invest in us Agreements & Forms Agreement Forms Master Patent IP License and Development Agreement Acceler … ging Medtech Summit Lionheart Health Announces the Filing of Provisional Patent Application For Bioelectric Enhanced Super PRF and Klotho Expressing Stem Cells Combination Lionheart Longevity & Wellness Announces Healthspan and Beauty Retreats in Partnership with Local Hotels Facebook X © Copyright Leonhardt Ventures | Website by FizzPOP Media
Lionheart Health Named as 2025 Top Implantable Stimulator Developer by MedTech Outlook Magazine | Newsworthy.ai About Us Solutions Top Categories Pricing Blog Curated News Community Login Register Free Lionheart Health Named as 2025 Top Implantable Stimulator Developer by MedTech Outlook Magazine – Lionheart Health, Inc., a leading biotech and medical device company focused on healthspan, longevity, and organ regeneration, has been recognized by MedTech Outlook as the Top Implantable Stimulator Developer of the Year. Aging Health Listen on NewsRamp Podcast Download PDF Huntington Beach, Califo … tlook as the Top Implantable Stimulator Developer of the Year. This prestigious award underscores Lionheart Health’s breakthrough work with its patented KlothoImplant™ and MicroImplant™ stimulator technologies. These advanced devices deliver precise bioelectric signaling sequences designed to control regenerative protein expression on demand. Such proteins play a critical role in homing stem cells to target organs, building new muscle, stimulating blood vessel growth, reducin … echnologies, healthcare providers, facilities, and institutions. Regarding this award, Brian Lasater, CTO of Lionheart Health, Inc. stated, “Our entire team is honored to be recognized by MedTech Outlook as the Top Implantable Stimulator Developer of 2025. Being acknowledged among the most impactful innovations of the year is truly gratifying. Lionheart Health has built a strong intellectual property foundation, with more than 500 issued and pending patent claims, multiple FD … ZE Healthspan competition and continues to advance toward the $81 million grand prize. ”See www.LionheartLongevity.com + www.lionhearthealthstim.com and www.LeonhardtVentures.com for more information. About Lionheart Health, Inc.: Lionheart Health, Inc. is a 2022 spinout of Leonhardt Ventures LLC that has been developing breakthrough medical innovations since 2022 which is focused on healthspan longevity and medical aesthetics. The Lionheart primary business model is to licen … cribe from within my email or responding to text messages with the word LEAVE . Submit Your AI-powered platform for creating, distributing, and analyzing press releases and news content. About Us Blog Contact Us Solutions Pricing Resources WordPress Plugin Become an Influencer Partner PR Glossary of Terms Community Legal Terms of Service Privacy
Leonhardt Ventures Fall 2012 Newsletter - Leonhardt Ventures Home About About us 2021 Top Achievements Leonhardt Ventures Portfolio Clinical Trials Listing Founder Bio Development Pipeline Investigator Initiated Study Request Procedure for Both Pre-Clinical and Clinical Studies Regenerative Medtech Media Company Logos LV Team Board of Directors Accelerator Core Team Portfolio Startups Boards Scientific Advisory Board Our Startups News Investors Invest in us Agreements & Forms Agreement Forms Master Patent IP License and Development Agreement Accelerator Membership Agreement Term Sheet 409 … the device is already approved for another more critical indication of use this application processing is expected to be short. MyoStim Pacers holds three pioneering patents from inventors Howard Leonhardt, Juan Chachques and Shinichi Kanno. These patents cover creating new blood vessels and new heart muscle from release of angiogenic and myogenic proteins that home stem cells to the heart and covert them to beating cardiomyocytes. The pioneering flagship claim is the ability … st cancer breasts successfully with stem cells + fat tissue. Patent pending via application filing by Hodgson, Russ & Goodyear – Inventor: Howard J. Leonhardt AortaCell This Northern California based company is focused on utilizing muscle stem cells to treat small aortic aneurysms and to reinforce the aneursymal necks in stent graft treatments. George Golik the founding President of AortCell died this year un-expectingly at age 53. A foundation is being set up where … Accelerator has hired Methven Law to file a California Qualification by Permit Application with the State of California with intent to initiate a $5 million capital raise – www.calxstars.com Cal-X Stars is forming the Cal-X Stars Startup Funding Club modeled after the successful Funders Club in Silicon Valley. Cal-X Stars has an unprecedented portfolio lineup of disruptive technology companies – http://calxstars.com/?page_id=33 BizBest named Cal-X Stars Business … izing social good companies and local investing. Cal-X is in early registration application stage with intent to file with the SEC to first be a listing service for Direct Public Offerings and later a full fledged stock exchange. In the meantime Cal-X serves as a business accelerator network. Cal-X intends to be a bridge between being private and
Device to Cut Orthodontic Treatment Time in Half – Leonhardt Ventures and OrthodontiCell File Provisional Patent Application – OrthodontiCell Skip to main content Skip to footer Technology Team News Scientific Articles Contact Technology Team News Scientific Articles Contact OrthodontiCell Blog Device to Cut Orthodontic Treatment Time in Half – Leonhardt Ventures and OrthodontiCell File Provisional Patent Application Device to Cut Orthodontic Treatment Time in Half – Leonhardt Ventures and OrthodontiCell File Provisional Patent Application Santa Monica, CA and Salt Lake … l-X Stars Business Accelerator, Inc. The Company has filed a provisional patent application in the U.S. Patent and Trademark Office for inventions relating to bioelectric stimulation controlled release of RANKL and a number of other proteins, including stem cell homing factor SDF-1, designed to accelerate tooth movement and cut in half the time required for orthodontic treatment with braces and clear aligners – the OrthodontiCell Tooth Movement Accelerator TM. Studies a … popmedia.com or Howard Leonhardt @ [email protected] . This provisional patent application was filed electronically utilizing www.legalzoom.com software. Safe Harbor This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the “safe harbor” created by those sections. All sta
Speakers - Sciinov Conference Overview About Become a Speaker Sponsor/Exhibit Organizer Info Speakers Speakers 2027 Japan Speakers 2026 Japan Speakers 2026 Dubai Speakers 2025 Edition 2 Speakers 2025 Speakers 2024 Edition 2 Speakers 2024 Speakers 2023 Speakers 2022 Speakers 2021 Speakers Q4 2020 Virtual Speakers Q3 2020 Virtual Speakers 2019 Program Scientific Sessions Scientific Program Brochure Download Partners Information Important Dates Venue Guidelines Publication Pricing / Registration Quick Downloads News Reports Past Events Submit Abstract Help & Support Registration Overview Abou … nes Publication Pricing / Registration Quick Downloads News Reports Past Events Submit Abstract Help & Support Registration 13th Edition: International Conference on Aging & Gerontology Home Speakers Howard Leonhardt April 14–15, 2027 @ Tokyo, Japan Register Now Submit Abstract Howard Leonhardt Executive Chairman & CEO, Leonhardt Ventures LLC , USA Title of Talk Bioelectric and Regenerative Multi-System Interventions for Healthspan Support: Translatio
Scott Jordan - Leonhardt Ventures Home About About us 2021 Top Achievements Leonhardt Ventures Portfolio Clinical Trials Listing Founder Bio Development Pipeline Investigator Initiated Study Request Procedure for Both Pre-Clinical and Clinical Studies Regenerative Medtech Media Company Logos LV Team Board of Directors Accelerator Core Team Portfolio Startups Boards Scientific Advisory Board Our Startups News Investors Invest in us Agreements & Forms Agreement Forms Master Patent IP License and Development Agreement Accelerator Membership Agreement Term Sheet 409a Valuation Accelerator Sim
Leonhardt Ventures News and Press Releases | PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Overv … ated to make your job easier. In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need. LEARN MORE « 1 --> 1 » Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected. Items per page: 25 per page 50 per page 75 per page 100 per page Contact PR Newswire Call PR Newswire at 888-776-0942 from 8 AM - 9 PM ET Chat with an Expert Contact Us … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
2018 Annual Report - Leonhardt Ventures Home About About us 2021 Top Achievements Leonhardt Ventures Portfolio Clinical Trials Listing Founder Bio Development Pipeline Investigator Initiated Study Request Procedure for Both Pre-Clinical and Clinical Studies Regenerative Medtech Media Company Logos LV Team Board of Directors Accelerator Core Team Portfolio Startups Boards Scientific Advisory Board Our Startups News Investors Invest in us Agreements & Forms Agreement Forms Master Patent IP License and Development Agreement Accelerator Membership Agreement Term Sheet 409a Valuation Accelerat … irginia. BioPace is moving forward with Dr. Alonso Moreno in Utah with numerous grant applications filed and patent agreement with the University of Utah. Valvublator has hired a President in Richard Henson and is moving towards building and testing prototypes for decalcifying and regenerating heart valves. PressureStim is moving into clinical studies in Korea and China for bioelectric blood pressure control. Our Brain group with CerebraCell presented at a number of major con … ncreaCell made it to the finals of the American Diabetes Association Innovation Award and is initiating research collaboration with the University of Miami. LiverCell and KidneyCell are moving into animal studies with McGowan Regenerative Medicine Institute in Pittsburgh. RegenaLung, EarCell, BladderCell, Instim, PolypStim and Wave all filed major new patent applications and moved closer to animal studies. BioLeonhardt Whole Body with BodStim filed to participate in the USC S … articipate in the USC SLAM Innovation competition and is preparing and NSF SBIR grant application. Our Cancer group with CancerCell has filed with the ethics committee at UCLA to begin a bioelectric treatment protocol in small animals. CancerCell has numerous issued patents and patents pending. In 2018 we filed over 180 new patent claims with the United State Patent and Trademark office and licensed in over 200 additional patent claims as well. The new filings included a full … esident and preparing prototypes for testing. BioPace – filed a number of grant applications. In licensed patent U of Utah. PressureStim – collaborating with researchers in China. Filed patents. Brain CerebraCell – preparing for animal studies. Presented at Neuro Tech Leaders Forum. Cosmetic and Personal Care HairCell – la
Leonhardt Ventures Technology Showcase @ JP Morgan Healthcare Conference Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimed … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Our Companies - Leonhardt Ventures Home About About us 2021 Top Achievements Leonhardt Ventures Portfolio Clinical Trials Listing Founder Bio Development Pipeline Investigator Initiated Study Request Procedure for Both Pre-Clinical and Clinical Studies Regenerative Medtech Media Company Logos LV Team Board of Directors Accelerator Core Team Portfolio Startups Boards Scientific Advisory Board Our Startups News Investors Invest in us Agreements & Forms Agreement Forms Master Patent IP License and Development Agreement Accelerator Membership Agreement Term Sheet 409a Valuation Accelerator Si … ody regeneration and Bod-Stim bioelectric yoga and athletic pants = secure SBIR grant add CIP claims to patent + build and test body suit prototypes – https://leonhardtventures.com/bioleonhardt-whole-body/  InStim Read More bioelectric real time inflammation management = develop prototype + complete animal studies – https://instimcell.com/  OrthoStim Read More bioelectric joint recovery treatment = conduct clinical registry study USA – www.ortho-stim.com ; COS … mpanies” within the accelerator/incubator share the same accelerator or venture fund checking account, accounts payable and receivable clerks, accountants, lawyers, web site developers, support staff, consultants, advisory board, conference rooms, offices, telephone systems, internet wifi accounts and even management personnel until they are advanced enough with a dedicated focused team in place with strength enough to be pushed out of the next to fly on their own and feed th
Leonhardt Increases Stake In Bioheart, Inc. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News &am … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Leonhardt Increases Stake In Bioheart, Inc. November 18, 2014 | 10 min read Twitter LinkedIn Facebook Email Print Santa Monica, CA – November 17th, 2014 - Leonhardt Ventures announced today it has increased its stake in Bioheart, Inc. via another debt conversion of $132,522.30. This follows $2,000,000 + $5 … c Guidant (4X), Magellan Group, Presidential Capital, Ascent Medical Technology Fund, Advent Morro, Tyco Ventures, Robin Hood Investments, NorthStar Investments & Minnesota Biomed Partners. Bioheart sold a license to Leonhardt and other patented stem cell delivery catheter technologies (4+ patents) to Abbott Laboratories for $900,000. Under this agreement with Abbott Laboratories they are responsible to defend Bioheart, Inc. against infringers at their expense. Bioheart, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Leonhardt Ventures To Enter Into Worldwide Strategic Collaboration With Neuro Code Tech Holdings For Customized Bioelectric Cancer Treatments - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufac … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Leonhardt Ventures To Enter Into Worldwide Strategic Collaboration With Neuro Code Tech Holdings For Customized Bioelectric Cancer Treatments February 22, 2017 | 10 min read Twitter LinkedIn Facebook Email Print Salt Lake City, Utah and Albuquerque, New Mexico, January 23rd, 2017/PRBuzz BREAK … e on the glycocalyx of the outer cell membrane is also part of the treatment by application of ions. The invention causes cancer cell death as a medical treatment using ultra-low voltage and amperage encoded signals which are reprogrammed from cancer cell communication signals. Dr. Santosh Kesari, Neuro Surgeon and CSO of CancerCell and CerebraCell, Leonhardt Ventures cos. commented: “We are delighted to collaborate with leading bioelectric personalized cancer therapy invento … previous related press release: Leonhardt Ventures and CerebraCell File Patent Application for Treating Cancer Tumors with Bioelectric Stimulation – http://mysocialgoodnews.com/leonhardt-ventures-cerebracell-file-patent-application-bioelectric-signals-halt-tumor-growth-regenerate-organs/ The Leonhardt team is also working on bioelectric neuro code signal reading that it believes can be an early detection system for cancers and organ regeneration to follow cancer tumor destru … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PancreaCell Unveils Total Pancreas Regeneration Device Ahead Of ADA - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach PancreaCell Unveils Total Pancreas Regeneration Device Ahead Of ADA June 13, 2016 | 4 min read Twitter LinkedIn Facebook Email Print SANTA MONICA, Calif. , June 10, 2016 /PRNewswire/ -- PancreaCell, a Leonhardt Ventures Co., today unveiled a patent pending combination micro regeneration stimulator and micr … g centers." The company announced last month the filing of a provisional patent application for special bioelectric signals designed to stop cancer tumor growth by stopping cell division and blood supply which may be used to treat pancreatic cancer in a presumably less toxic way than chemo or radiation and with the benefit of a full regeneration program to follow eradication of the tumors - http://mysocialgoodnews.com/leonhardt-ventures-cerebracell-file-patent-application-bio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Leonhardt Adds HIF-1 Alpha To Estate Of Bioelectric Controlled Release Regenerative Proteins - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioMidwest Leonhardt Adds HIF-1 Alpha To Estate Of Bioelectric Controlled Release Regenerative Proteins June 13, 2017 | 5 min read Twitter LinkedIn Facebook Email Print Salt Lake City, Utah and Santa Monica, CA – June 8th, 2017 (PRBUZZ) — Leonhardt’s Launchpads, an organ regeneration and recover … ovation/startup accelerator today announced that it has filed a new patent application claim for the controlled expression of Hypoxia Inducible Factor 1 (HIF 1 Alpha). HIF 1 Alpha is a powerful organ regeneration protein. This patent will be sub-licensed exclusively organ by organ to 26 unique organ regeneration focused startups within the Leonhardt led innovation accelerators in Utah and California including BioLeonhardt heart, AortaCell aorta,  … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Leonhardt Announces Vibrational Energy Device For Preventing Blood Clots Provisional Patent Application And License Agreements - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Leonhardt Announces Vibrational Energy Device For Preventing Blood Clots Provisional Patent Application And License Agreements May 25, 2017 | 5 min read Twitter LinkedIn Facebook Email Print Santa Monica, CA and Salt Lake City, UT, May 23, 2017 (PRBUZZ) -- Leonhardt's Launchpads announces today that … dt's Launchpads announces today that the Company has filed a provisional patent application to expand its current intellectual property portfolio to now include a harmonic vibrational resonance energy device to prevent blood clots, plaque and calcification on blood contact surfaces such as circulatory assist pumps and heart valves. The new patent application will strengthen the Company's overall patent coverage related in organ regeneration and recovery technologi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Leonhardt's Launchpads Announces Filing of Patent for Bioelectric Stimulation Controlled Klotho Expression - Powerful Anti-aging and Regeneration Promoting Protein - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Leonhardt’s Launchpads Announces Filing of Patent for Bioelectric Stimulation Controlled Klotho Expression - Powerful Anti-aging and Regeneration Promoting Protein March 13, 2019 | 5 min read Twitter LinkedIn Facebook Email Print Leonhardt’s Launchpads, a Los Angeles, Salt Lake City and Pittsburgh based in … ologics based organ regeneration and recovery, today announced filing of patent application for bioelectrical stimulation signaling sequences able to control the release of Klotho, Device, programmed bioelectric signaling sequences and methods for the controlled expression of Klotho on demand Leonhardt's Launchpads, a Los Angeles, Salt Lake City and Pittsburgh based innovation and startup accelerator focused on bioelectric and biologics based organ regeneration and rec … ologics based organ regeneration and recovery, today announced filing of patent application for bioelectrical stimulation signaling sequences able to control the release of Klotho, a known powerful anti-aging and regeneration promoting protein, by up t o 465% increase over baseline levels. The technology described in the patent involves precise bioelectric signaling sequences that communicate with the DNA and cell membranes within stimulated tissues to … r have a no additional fee exclusive ownership license for their specific organ application. Leonhardt's Launchpads has 30 startups in these technology groups - Heart & Cardiovascular (9), Brain (1), Cosmetic & Personal Care (7), Major Organ Regeneration (12) and Cancer (1) - https://leonhardtventures. com/our-companies/  
Leonhardt Ventures Announces Filing of Patent for Bioelectric S100A Expression for Organ Healing - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Leonhardt Ventures Announces Filing of Patent for Bioelectric S100A Expression for Organ Healing December 29, 2021 | 6 min read Twitter LinkedIn Facebook Email Print Leonhardt Ventures LLC, an innovation and venture creation company focused on the convergence of bioelectrics and biologics for organ regener … porting data for the expression of the S100A1 protein was submitted to a patent application filed earlier this year. Mission Viejo, California, United States, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Leonhardt Ventures LLC, an innovation and venture creation company focused on the convergence of bioelectrics and biologics for organ regeneration, announced today that additional pre-clinical supporting data for the expression of the S100A1 protein was submit … ng data for the expression of the S100A1 protein was submitted to a patent application filed earlier this year. S100A1 is a member of the S100 family of calcium-binding proteins and is a critical lead regulator of cardiac performance and vascular biology. In cardiomyocytes, S100A1 is known to substantially improve Ca2+ handling and contractile performance. Additionally, S100A1 targets the cardiac sarcomere and mitochondria, reducing pre-contractile tension and … has exclusively licensed this patent-pending technology for the application of use in heart regeneration to BioLeonhardt LTP www.bioleonhardt.com . BioLeonhardt has planned a new round of large animal studies at the California Medical Innovations Institute in North San Diego County for the first quar
U.S. Patent for Bioelectric Expression of Klotho, a Key Longevity and Disease-Fighting Protein Issued to Leonhardt Ventures - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach U.S. Patent for Bioelectric Expression of Klotho, a Key Longevity and Disease-Fighting Protein Issued to Leonhardt Ventures October 20, 2022 | 7 min read Twitter LinkedIn Facebook Email Print Leonhardt Ventures, LLC is pleased to announce the United States Patent and Trademark Office (USPTO) has issued U.S … A, is a venture creation lab, product invention development laboratory, venture fund, and angel mentoring network. The Leonhardt team introduced the PolyCath TM line of cardiovascular balloon catheters in the 1980s, the TALENT TM (Taheri-Leonhardt) stent graft, StentValve, ProCell stem cell delivery catheters, PENSIL intravascular lung, RadiCath electromagnetic radiation delivery catheters, and bioelectric stimulators for improving blood flow in the 1990s. In 1987 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Leonhardt Ventures Files Patent For Heart Valve Regeneration - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rele … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Leonhardt Ventures Files Patent For Heart Valve Regeneration July 15, 2016 | 6 min read Twitter LinkedIn Facebook Email Print July 14th, 2016 - Santa Monica, Ca and Salt Lake City, UT - Leonhardt Ventures www.leonhardtventures.com announced today that its startup Valvublator has filed with the U.S.PTO a pr … ay that its startup Valvublator has filed with the U.S.PTO a provisional patent application covering devices and methods for heart valve regeneration designed to help a patient keep their own heart valve instead of getting an artificial implant. Howard J. Leonhardt the Founder of Leonhardt Ventures is the sole inventor. Link to Valvublator Animation Video Here > www.leonhardtventures.com/valvublator/ Components of the invention include: 1. 9FR Deflecting tip guiding cathet … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Leonhardt Ventures Files Patent for Bioelectric Diabetes Reversal Treatment via FABp4 Regulation and Klotho Regulation - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business J … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Leonhardt Ventures Files Patent for Bioelectric Diabetes Reversal Treatment via FABp4 Regulation and Klotho Regulation December 30, 2021 | 6 min read Twitter LinkedIn Facebook Email Print Leonhardt Ventures LLC announced today filing of a patent application covering bioelectric controlled down regulation o … OBE NEWSWIRE) -- Leonhardt Ventures LLC announced today filing of a patent application covering bioelectric controlled down regulation of FABp4 and up regulation of klotho for the potential purpose of reversing type 1 and 2 diabetes. Published studies have documented that serum FABp4 levels are higher in type 2 diabetic patients compared to healthy individuals and klotho levels are lower. FABp4 over expression interferes with the ability o … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Leonhardt And Genovese File Patent For Bioelectric Controlled Expression Of PDGF A Powerful Organ Regeneration Cytokine - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioMidwest Leonhardt And Genovese File Patent For Bioelectric Controlled Expression Of PDGF A Powerful Organ Regeneration Cytokine December 20, 2016 | 5 min read Twitter LinkedIn Facebook Email Print Salt Lake City, Utah and Los Angeles, CA - December 19, 2016 (PRBUZZ) -- Leonhardt's Launchpads, an organ regeneration fo … f organ degeneration today announced that it has filed a new provisional patent application for the controlled expression of platelet derived growth factor (PDGF). PDGF is a powerful organ regeneration protein. This patent will be sub-licensed exclusively organ by organ to 25 unique organ regeneration focused startups within the Leonhardt led innovation accelerators in Utah and California including BioLeonhardt heart, AortaCell aorta, CerebraCell brain, EyeCell eye, Stem Cell … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Leonhardt Ventures Announces Issuance of Pioneering U.S. Patent for Multi-Modality Customized Bioelectric Treatment of Cancer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bus … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Leonhardt Ventures Announces Issuance of Pioneering U.S. Patent for Multi-Modality Customized Bioelectric Treatment of Cancer December 22, 2021 | 7 min read Twitter LinkedIn Facebook Email Print Leonhardt Ventures LLC, a pioneer in developing bioelectric and biologic innovations for organ regeneration and … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Leonhardt Ventures Announces Launch of Research Program Using Patent Pending Klotho Expressing Mesenchymal Stem Cells for Multiple Applications in Combination with Bioelectric Protein Expressions - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu S … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Leonhardt Ventures Announces Launch of Research Program Using Patent Pending Klotho Expressing Mesenchymal Stem Cells for Multiple Applications in Combination with Bioelectric Protein Expressions January 26, 2022 | 8 min read Twitter LinkedIn Facebook Email Print Leonhardt Ventures LLC, a Mission Viejo, Ca … A, is a venture creation lab, product invention development laboratory, venture fund, and angels network. The Leonhardt team introduced the PolyCath line of cardiovascular balloon catheters in the 1980s, the TALENT (Taheri-Leonhardt) stent graft, StentValve, ProCell stem cell delivery catheters, PENSIL intravascular lung, RadiCath electromagnetic radiation delivery catheters, and bioelectric stimulators for improving blood flow in the 1990s. Since then, the primary focus has … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Leonhardt Ventures Release: World Stem Cell Summit 2014 December 5th Keynote Speaker Howard Leonhardt - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell an … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Leonhardt Ventures Release: World Stem Cell Summit 2014 December 5th Keynote Speaker Howard Leonhardt December 1, 2014 | 7 min read Twitter LinkedIn Facebook Email Print Santa Monica, CA, Dec. 1st, 2014 /PRBuzz/-- Howard Leonhardt of Leonhardt Ventures and the Cal-X Stars Business Accelerator, Inc. team wi … Cal-X Crowdfund Connect www.calxcrowdfund.com: Helping life science firms build fund raising campaigns working with approved high quality portals and service providers - http://www.calstockexchange.com/healthcare-biotech-medtech-crowdfunding/ What we do CLICK HERE - http://www.calstockexchange.com/cal-x-crowdfund-connect-what-do-we-do/ Contact: Howard Leonhardt, Leonhardt Ventures' Cal-X Stars Business Accelerator, Inc., 1531 6th Street, Unit 401, Santa Monica, California, 90 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Lionheart Health Inc. Newsroom | Newsroom | Newsworthy.ai Lionheart Health Inc. Newsroom Visit Website → Press Releases Lionheart Health Announces Enrollment Beginning for Lionheart Klotho-Up™ Study March 27, 2026 • Huntington Beach, California Lionheart Health, Inc. has started enrollment for its Lionheart Klotho-Up™ Study, a program to evaluate a wellness and bioelectric intervention for healthy aging. The study includes nutrition, exercise, and optional therapies to assess muscle, brain, and immune health. Contact: Natalie Tinnirello • Email Contact Dr. Joseph C. Maroon, MD, FACS Joins Scie
Lionheart Health, Inc. to Present at Upcoming LSI US ’25 Emerging Medtech Summit - Leonhardt Ventures Home About About us 2021 Top Achievements Leonhardt Ventures Portfolio Clinical Trials Listing Founder Bio Development Pipeline Investigator Initiated Study Request Procedure for Both Pre-Clinical and Clinical Studies Regenerative Medtech Media Company Logos LV Team Board of Directors Accelerator Core Team Portfolio Startups Boards Scientific Advisory Board Our Startups News Investors Invest in us Agreements & Forms Agreement Forms Master Patent IP License and Development Agreement Accele … ealthspan. In December 2023 they won the coveted Abbvie Allergan Aesthetics ULP Award for Innovation in Medical Aesthetics. Recent Posts Researchers at Leonhardt Ventures Unveil E-Stent™ A Breakthrough Bioelectric Stimulation Stent Tech Platform Two innovation leaders team up to launch clinical study aimed to prove improvement in wound healing especially in patients facing limb loss Lionheart Health, Inc. to Present at Upcoming LSI US ’25 Emerging Medtech Summit Lionheart Hea … ging Medtech Summit Lionheart Health Announces the Filing of Provisional Patent Application For Bioelectric Enhanced Super PRF and Klotho Expressing Stem Cells Combination Lionheart Longevity & Wellness Announces Healthspan and Beauty Retreats in Partnership with Local Hotels Facebook X © Copyright Leonhardt Ventures | Website by FizzPOP Media
About – Lionheart Longevity & Wellness Skip to main content Skip to footer Membership Treatments About Locations Our Locations Newport Beach Manhattan Sublet Space Access Licensing Contact Membership Treatments About Locations Our Locations Newport Beach Manhattan Sublet Space Access Licensing Contact book now Who We Are About Us Merging Health, Beauty, and Science for Lasting Vitality schedule a consultation our locations The Essence Of Longevity Innovation is a life-changing force. It transforms the way we live, heal, and evolve. It has the power to redefine what’s possible—reshapi … ional cardiovascular research. His work bridges laboratory science and clinical application. World expert in stem cell regeneration therapies. 160+ peer reviewed publications. 2 patents. Marc Penn, MD, PhD Dr. Penn is a cardiovascular scientist with expertise in regenerative medicine and heart failure biology. He supports translational therapeutic advancement at Cleveland Clinic and other institutions. 120+ peer reviewed publications and 5+ patents issued and pending. Catheri … patient outcome evaluation. She supports protocol refinement and translational application. Dr. Berkey is a Functional Medicine doctor with over 30 years experience. Nephrology & Kidney Health Samer Banihani, MD Dr. Banihani is a nephrologist specializing in kidney health and renal disease management. He advises on regenerative and longevity-focused renal strategies. Clinical Longevity & Integrative Medicine Patrick Sewell, MD Dr. Sewell focuses on integrative and re
Leonhardt Ventures | Howard Leonhardt, CEO - Life Science Intelligence USA Europe Asia Compass AI Login Medtech Pro Login Events Featured Our Next Event Register for LSI Asia ‘26 Who's Attending? See LSI Asia '26 Attendee List Events Overview See Who's Attending Who Attends Why Present Upcoming Summits LSI Asia ‘26 LSI Europe '26 LSI USA ‘27 Past Summits LSI Asia ‘25 LSI Europe ‘25 LSI USA ‘26 Archives Insights Featured Just Launched Compass AI New Report Emerging Innovators Report Compass Al Emerging Innovators Report Market Data Custom Research Magazine Featured May Edition Explore Latest Ed … r all the money we spent in all the years we spent on regenerating hearts would apply to other organs. And now we've developed a full portfolio and heart and cardiovascular. One product second heart was a stent that has a pump inside of it a actual physical pump. And it was designed to offload the heart while we were regenerating hearts. Well, we met with a top heart failure doctors in the United States and they told us we want that product separate. So that's the o … r all the money we spent in all the years we spent on regenerating hearts would apply to other organs. And now we've developed a full portfolio and heart and cardiovascular. One product second heart was a stent that has a pump inside of it a actual physical pump. And it was designed to offload the heart while we were regenerating hearts. Well, we met with a top heart failure doctors in the United States and they told us we want that product separate. So that's the o
US10646644B2 - Stimulator, pump and composition - Google Patents US10646644B2 - Stimulator, pump and composition - Google Patents Stimulator, pump and composition Download PDF Info Publication number US10646644B2 US10646644B2 US15/460,129 US201715460129A US10646644B2 US 10646644 B2 US10646644 B2 US 10646644B2 US 201715460129 A US201715460129 A US 201715460129A US 10646644 B2 US10646644 B2 US 10646644B2 Authority US United States Prior art keywords bioelectric signal regeneration minutes target tissue Prior art date 2016-03-15 Legal status (The legal status is an assumption and is not a legal c … is and makes no representation as to the accuracy of the status listed.) Active Application number US15/460,129 Other versions US20170266371A1 ( en Inventor Howard J. Leonhardt Jorge Genovese Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Calxstars Business Accelerator Inc Leonhardt Ventures LLC Original Assignee Calxstars Business Accelerator Inc Prio … 15 Priority to US15/460,129 priority Critical patent/US10646644B2/en 2017-03-15 Application filed by Calxstars Business Accelerator Inc filed Critical Calxstars Business Accelerator Inc 2017-09-21 Publication of US20170266371A1 publication Critical patent/US20170266371A1/en 2017-11-14 Priority to US15/812,760 priority patent/US10960206B2/en 2018-07-27 Assigned to Cal-X Stars Business Accelerator, Inc. reassignment Cal-X Stars Business Accelerator, Inc. ASSIGNMENT OF ASSIGNORS … lication of US10646644B2 publication Critical patent/US10646644B2/en 2020-05-12 Application granted granted Critical 2020-06-26 Priority to US16/913,964 priority patent/US11691007B2/en 2021-03-29 Priority to US17/216,423 priority patent/US12109410B2/en 2021-06-15 Assigned to LEONHARDT VENTURES LLC reassignment LEONHARDT VENTURES LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Cal-X Stars Business Accelerator, Inc. 2021-07-06 Priority to US17/368,49 … ors A61N1/375 — Constructional arrangements, e.g. casings Definitions the application relates generally to the field of medical devices and associated treatments, and more specifically to precise bioelectrical stimulation of a subject's tissue, augmented with the administration of a composition comprising, among other things, stem cells
Leonhardt’s Launchpads Accelerator Announces Demo Days and Showcases September in San Francisco and Palo Alto for Organ Regeneration and Recovery Focused Startups | Bio Leonhardt BioLeonhardt Technology About Team Executive Summary Supporting Articles PreClinical Study Protocol II News Contact Select Page Leonhardt’s Launchpads Accelerator Announces Demo Days and Showcases September in San Francisco and Palo Alto for Organ Regeneration and Recovery Focused Startups by bioleohardnew | Jul 18, 2019 | Uncategorized Leonhardt’s Launchpads www.leonhardtventures.com an innovation and startup a … f studies the companies make no claims of proven safety or efficacy yet for any application of use. Our business model is to align with a strategic partner to carry each organ-specific application through multiple larger scale double-blinded, randomized, placebo-controlled studies of statistical significance to prove out both the safety and efficacy. “We are committed to designing and implementing well-controlled pre-clinical and clinical studies to prove out the safety … tential therapeutic solutions. No other group is working as hard as our team to apply these breakthroughs into patient benefit in the near future”. states Alex Richardson Vice President of Engineering and Product Development @ Leonhardt’s Launchpads About Leonhardt’s Launchpads: Founded in 2008 in California an innovation and startup accelerator focused on applying bioelectrics and biologics to organ regeneration and recovery. 30 startups in current 2019 por
Leonhardt's Launchpads Organ Regeneration Technology Showcase January 8th San Francisco - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Leonhardt’s Launchpads Organ Regeneration Technology Showcase January 8th San Francisco December 29, 2017 | 8 min read Twitter LinkedIn Facebook Email Print Today Leonhardt’s Launchpads, an innovation accelerator focused on organ regeneration technologies, announced a technology showcase Monday January 8th, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Comments of H. Leonhardt on JOBS Act Title III Howard J Leonhardt, CEO Leonhardt Ventures and CalXStars Business Accelerator - Co-Leader StartupCalifornia, Santa Monica, California, September 29, 2012 (File name: hjleonhardt5451.htm) (Attached File #1: hjleonhardt6213.pdf) --> Sep. 29, 2012 Howard J Leonhardt, CEO Leonhardt Ventures and CalXStars Business Accelerator - Co-Leader StartupCalifornia, Santa Monica, California --> Subject: File No. JOBS Act Title III From: Howard J Leonhardt Affiliation: CEO Leonhardt Ventures and CalXStars Business Accelerator - Co-Leader StartupCalifornia … s were the 2nd highest burden. We had to complete 3 years of audits twice after Grant Thornton dropped out and would not transfer their files to the new accounting firm. The only reason Grant Thornton dropped out was that our cash reserves were running low with the many delays. The cost and complexity of raising capital is most burdensome on women, minorities, youth and people like me that were the children of blue collar mid or lower income families. When I first went to rai … tal will be greatly improved. Leonhardt Ventures www.leonhardtventures.com is a fund and angel network that not only finances businesses but nurtures them. We created Cal-X Stars Business Accelerator www.calxstars.com to nurture companies following the Dolphin Tank model innovated by Amy Millman of Springboard Enterprises in Washington D.C. In fact we are sponsoring all the Dolphin Tank Panels in California which included the one last week in Long Beach. Cal-X Stars Business … listing service for DPOs in California first and is in the process of preparing application to register with the SEC to be a full fledged stock exchange (with limited liquidity = sell orders may take up to 90 days to fill, no day trading, no short trading, only social good mission companies with an emphasis on local investing). Right now Cal-X is a movement for change and and is tied to the Cal-X Stars Business Accelerator. We are in dialogue with the ASSOB Exchange in Austra … ging Firms, Inc. of San Diego. 5. We believe the SEC should quickly approve the application submitted by The California Stock Xchange to provide an intermediate liquidity step between being private with no liquidity and being on NASDAQ or NYSE with full liquidity. 90 days for executing sell orders, giving the company a fair chance to find a buyer
Founder Bio - Leonhardt Ventures Home About About us 2021 Top Achievements Leonhardt Ventures Portfolio Clinical Trials Listing Founder Bio Development Pipeline Investigator Initiated Study Request Procedure for Both Pre-Clinical and Clinical Studies Regenerative Medtech Media Company Logos LV Team Board of Directors Accelerator Core Team Portfolio Startups Boards Scientific Advisory Board Our Startups News Investors Invest in us Agreements & Forms Agreement Forms Master Patent IP License and Development Agreement Accelerator Membership Agreement Term Sheet 409a Valuation Accelerator Simp … good impact stock exchange currently operating the Cal-X 30 Social Good Impact fund powered by Motif Investing- www.calstockexchange.com – He founded Cal-X Crowdfund Connect www.calxcrowdfund.com a crowdfunding campaign management co. and Cal-X Stars Business Accelerator, Inc. www.calxstars.com a business incubator and accelerator focused on cardiovascular life sciences and social good impact innovations. There are 30 regenerative medtech and regenerative economy startups in
Lionheart Health, Inc. is developing a whole body regeneration chamber. A womb for adults AI and robotics supported. | Howard J. Leonhardt
Lionheart Health, Inc. | Best Micro Bioelectric Implantable Stimulator 2025 About Us Conference Advertise With Us Home Topics Cancer Care Cardiovascular Devices Dental Care Devices Drug Delivery Solutions Endoscopy ENT Devices In Vitro Diagnostics Medical Aesthetics Medical Device Consulting Medical Device Design and Development Medical Device Regulatory and Compliance Medical Equipment Mobility Devices and Aids Ophthalmic Orthopedic Patient Monitoring Devices Physiotherapy and Pain Management Regenerative Medicine Spine Solutions Surgical Devices and Instruments Vein Detection Vision Care Can … company has partnered with OEM manufacturers to offer FDA-cleared devices that apply its core technology to applications such as muscle strengthening, arthritis therapy, and clot prevention. Its BodStim ™ Suit, a wearable system, uses similar bioelectric stimulation to enhance exercise and support muscle health as we age. The team behind these innovations blends deep engineering and medical expertise. Chief Technology Officer Brian Lassater has driven over a hundred design b
Leonhardt Ventures LLC and Licensee Lionheart Health, Inc. Granted U.S. Patent for Bioelectric Stem Cell Homing, Proliferation and Differentiation Control - Leonhardt Ventures Home About About us 2021 Top Achievements Leonhardt Ventures Portfolio Clinical Trials Listing Founder Bio Development Pipeline Investigator Initiated Study Request Procedure for Both Pre-Clinical and Clinical Studies Regenerative Medtech Media Company Logos LV Team Board of Directors Accelerator Core Team Portfolio Startups Boards Scientific Advisory Board Our Startups News Investors Invest in us Agreements & Forms … ging Medtech Summit Lionheart Health Announces the Filing of Provisional Patent Application For Bioelectric Enhanced Super PRF and Klotho Expressing Stem Cells Combination Lionheart Longevity & Wellness Announces Healthspan and Beauty Retreats in Partnership with Local Hotels Facebook X © Copyright Leonhardt Ventures | Website by FizzPOP Media
Leonhardt Ventures LLC Surpasses Historic Milestone with Over 1 Million Patients Treated with Its Inventions and Technology Platforms – Lionheart Longevity & Wellness Skip to main content Skip to footer Membership Treatments About Locations Our Locations Newport Beach Manhattan Sublet Space Access Licensing Contact Membership Treatments About Locations Our Locations Newport Beach Manhattan Sublet Space Access Licensing Contact book now Lionheart News Leonhardt Ventures LLC Surpasses Historic Milestone with Over 1 Million Patients Treated with Its Inventions and Technology Platforms H … s, KlothoPod II and Lionheart Octopus TM which is currently in the UCI Capstone grant supported program. Lionheart Health, Inc., a commercialization affiliate of Leonhardt Ventures LLC, is currently advancing multiple bioelectric stimulation and regenerative medicine programs and is a top 40 semi-finalist in the $101 million XPRIZE Healthspan competition. The team recently also won the Abbive Allergan ULP Innovation Award. About Leonhardt Ventures LLC Leonhardt Ventures LLC f
Team | Bio Leonhardt BioLeonhardt Technology About Team Executive Summary Supporting Articles PreClinical Study Protocol II News Contact Select Page BioLeonhardt Management Howard Leonhardt – Chairman of the Board & CEO Howard J. Leonhardt, Chairman of the Board, Executive Chairman, Chief Technology Officer, MyoStim Pacers, Inc. Leonhardt also serves as Executive Chairman of Leonhardt Ventures a cardiovascular life science plus social good impact investment fund, angel network and innovation accelerator www.leonhardtventures.com. He is an inventor and serial entrepreneur with over 20 issue … Heart Transplant and Mechanical Assist Program, and Director of the Cardiology Fellowship Program 2005-2007: Founding Director of the Lillehei Heart Institute, U of MN 2007-2010: Chair of the combined Division of Cardiology Georgetown University and Washington Hospital Center Proctor Harvey Distinguished Professor of Cardiology, Georgetown Univ Director of the Heart Transplant and Mechanical Support Program Director of the Cardiology Fellowship Program 2010-2013: Chairman th … dward C. Wright Professor of Cardiovascular Medicine Director of the Cardiology Fellowship Program 2012-2013: Director of the Cardiovascular Institute 2013-2016: Director of Heart Failure Morton Plant Hospital 2016-current: Chief Medical Officer, Leonhardt Ventures 1988-2009: Founder and Chair: Working Group of Transplant Cardiologists 1995-1997: President of American Society of Transplant Physicians 1997-1998: President of International Society of Heart and Lung Transplantat … of Staff of USC Keck. Get in touch with us Name Email Address Message 13 + 12 = Submit Facebook X © Copyright Bio-Leonhardt | Website by: FizzPOP Media
Home - Leonhardt Ventures Home About About us 2021 Top Achievements Leonhardt Ventures Portfolio Clinical Trials Listing Founder Bio Development Pipeline Investigator Initiated Study Request Procedure for Both Pre-Clinical and Clinical Studies Regenerative Medtech Media Company Logos LV Team Board of Directors Accelerator Core Team Portfolio Startups Boards Scientific Advisory Board Our Startups News Investors Invest in us Agreements & Forms Agreement Forms Master Patent IP License and Development Agreement Accelerator Membership Agreement Term Sheet 409a Valuation Accelerator Simple Agre … e are a venture creation lab, product invention development laboratory, venture fund, angels network and feeder of innovations to the Cal-Xelerator startup launch accelerator and the Cal-X Stars 5 Year Business Accelerator. Howard J. Leonhardt Founder “Leadership is leading by example – be the most enthusiastic, be the most curious – read everything you can possibly get your hands on that helps advance your project, be the most complimentary and appreciative
Howard Leonhardt - Leonhardt Ventures Home About About us 2021 Top Achievements Leonhardt Ventures Portfolio Clinical Trials Listing Founder Bio Development Pipeline Investigator Initiated Study Request Procedure for Both Pre-Clinical and Clinical Studies Regenerative Medtech Media Company Logos LV Team Board of Directors Accelerator Core Team Portfolio Startups Boards Scientific Advisory Board Our Startups News Investors Invest in us Agreements & Forms Agreement Forms Master Patent IP License and Development Agreement Accelerator Membership Agreement Term Sheet 409a Valuation Accelerator